Trends in Treatment and Survival of Gallbladder Cancer in the Netherlands; Identifying Gaps and Opportunities from a Nation-Wide Cohort
Open Access
- 9 April 2020
- Vol. 12 (4), 918
- https://doi.org/10.3390/cancers12040918
Abstract
Gallbladder cancer (GBC) is rare in Western populations and data about treatment and outcomes are scarce. This study aims to analyze survival and identify opportunities for improvement using population-based data from a low-incidence country. GBC patients diagnosed between 2005 and 2016 with GBC were identified from the Netherlands Cancer Registry. Patients were grouped according to time period (2005–2009/2010–2016) and disease stage. Trends in treatment and overall survival (OS) were analyzed. In total 1834 patients were included: 661 (36%) patients with resected, 278 (15%) with non-resected non-metastatic, and 895 (49%) with metastatic GBC. Use of radical versus simple cholecystectomy (12% vs. 26%, p < 0.001) in early (pT1b/T2) GBC increased. More patients with metastatic GBC received chemotherapy (11% vs. 29%, p < 0.001). OS improved from 4.8 months (2005–2009) to 6.1 months (2010–2016) (p = 0.012). Median OS increased over time (2005–2009 vs. 2010–2016) in resected (19.4 to 26.8 months, p = 0.038) and metastatic (2.3 vs. 3.4 months, p = 0.001) GBC but not in unresected, non-metastatic GBC. In early GBC, patients with radical cholecystectomy had a median OS of 76.7 compared to 18.4 months for simple cholecystectomy (p < 0.001). Palliative chemotherapy showed superior (p < 0.001) survival in metastatic (7.3 versus 2.1 months) and non-resected non-metastatic (7.7 versus 3.5 months) GBC. In conclusion, survival of GBC remains poor. Radical surgery and palliative chemotherapy appear to improve prognosis but remain under-utilized.Funding Information
- ADP (55695817)
This publication has 33 references indexed in Scilit:
- Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancerAlimentary Pharmacology & Therapeutics, 2011
- Systematic review on the surgical treatment for T1 gallbladder cancerWorld Journal of Gastroenterology, 2011
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerThe New England Journal of Medicine, 2010
- Evolving Treatment Strategies for Gallbladder CancerAnnals of Surgical Oncology, 2009
- Helicobacter species in cancers of the gallbladder and extrahepatic biliary tractBritish Journal of Cancer, 2008
- Gallbladder cancer (GBC): 10‐year experience at Memorial Sloan‐Kettering Cancer Centre (MSKCC)Journal of Surgical Oncology, 2008
- Immediate re-resection of T1 incidental gallbladder carcinomas: a survival analysis of the German RegistrySurgical Endoscopy, 2008
- Obesity and the risk of gallbladder cancer: a meta-analysisBritish Journal of Cancer, 2007
- Surgical Treatment of 724 Carcinomas of the Gallbladder Results of the French Surgical Association SurveyAnnals of Surgery, 1994
- Completeness of Cancer Registration in Limburg, the NetherlandsInternational Journal of Epidemiology, 1993